Last update 07 Nov 2024
Zuclomifene(Veru Healthcare, Inc.)
Last update 07 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine, 2-(p-(β-chloro-α-phenylstyryl)phenoxy)triethylamine + [10] |
Target |
Mechanism ERs agonists(Estrogen receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC32H36ClNO8 |
InChIKeyPYTMYKVIJXPNBD-OQKDUQJOSA-N |
CAS Registry7619-53-6 |
Related
13
Clinical Trials associated with Zuclomifene(Veru Healthcare, Inc.)Impact of clomiphene on semen parameters in normogonadotrophic idiopathic male infertility: a double-blind randomised placebo-controlled trial
Comparison of the effect of three drugs clomiphene, letrozole and gonadotropin on the dominant follicle and pregnancy in infertile women with polycystic ovaries: a single-blind randomized controlled trial
Letrozole or Clomifene, with or without metformin, for ovulation induction in women with polycystic ovary syndrome: a 2x2 factorial design randomised trial (The LOCI trial) - LOCI: Letrozole Or Clomifene for Ovulation Induction
100 Clinical Results associated with Zuclomifene(Veru Healthcare, Inc.)
Login to view more data
100 Translational Medicine associated with Zuclomifene(Veru Healthcare, Inc.)
Login to view more data
100 Patents (Medical) associated with Zuclomifene(Veru Healthcare, Inc.)
Login to view more data
2,720
Literatures (Medical) associated with Zuclomifene(Veru Healthcare, Inc.)31 Dec 2024Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Statement of Retraction: Combined metformin and clomiphene citrate
versus
highly purified FSH for ovulation induction in clomiphene-resistant PCOS women: a randomised controlled trial
01 Dec 2024GYNECOLOGICAL ENDOCRINOLOGY
Is combined letrozole and clomiphene superior to either as monotherapy: a systemic review and meta-analysis based on clinical trials.
Review
Author: El-Gayar, Mona ; Ashkar, Anusha ; Siddiqui, Fatima Zulfiqar ; Irfan, Shayan A ; Ali Baig, Mirza Mehmood ; Jadoon, Bismeen
OBJECTIVE:
This research was conducted to assess the therapeutic advantage of combined letrozole and clomiphene citrate versus monotherapy for polycystic ovarian syndrome (PCOS) patients.
STUDY DESIGN:
Five databases were searched using the search string: (letrozole and clomiphene) AND (clomiphene OR clomiphene citrate OR CC) AND (letrozole OR LE) AND (ovulation induc* OR fertility induc* OR fertility preserv*) AND (polycystic ovarian syndrome OR PCOS). All statistical analyses were conducted in Review Manager 5.4.1. Random effect-effect model was used to pool risk ratio (RR), mean difference (MD), and odds ratio (OR) and their corresponding 95% confidence interval (CI). Moreover, qualitative analysis was conducted to qualitatively analyze ovulation, secondary outcomes, and cycle characteristics.
RESULTS:
One clinical trial and three randomized clinical trials (RCTs) were used in the study. Two studies were used in a quantitative analysis showing that combination was superior for ovulation induction (RR = 1.86 [1.37, 2.53]; p < 0.0001; I2 = 0%), but the number of follicles ≥15 mm was significantly associated with the combination (MD = 0.40[0.14, 0.66]; p = 0.002; I2 = 0%). On subgroup analysis, only hot flushes were significantly associated with the combination (RR = 2.67[1.12, 6.36]; p = 0.03; I2 = 0%). The meta-analysis of two studies reported a significantly higher ovulation rate and number of dominant follicles in the combination therapy group compared with the LE alone arm but no significant difference in pregnancy rate, endometrial thickness, and adverse events.
CONCLUSION:
Our study demonstrates a significant effect of the combination on ovulation induction. The combination yielded a better chance of conception and viable pregnancy. Further studies are needed to determine the live birth rate. HighlightsCombined Letrozole and Clomiphene is superior to either of these drugs alone for ovulation induction in PCOS.Our results conclude that the combination results in better ovulation, cycle characteristics, and secondary changes.Only the incidence of hot flushes as an adverse effect is increasingly reported in combination.
01 Sep 2024Translational Andrology and Urology
Safety and efficacy of enclomiphene and clomiphene for hypogonadal men
Article
Author: Saffati, Gal ; Kronstedt, Shane ; Hinojosa-Gonzalez, David E ; Lipshultz, Larry I. ; Hinojosa-Gonzalez, David E. ; Orozco Rendon, Daniela ; Kassab, Jordan ; Khera, Mohit ; Lipshultz, Larry I
Background:
Both clomiphene citrate and its isomer, enclomiphene, have become widespread within urologic practice; thus, understanding these medications' comparative benefits and risks is crucial for optimizing treatment and providing improved therapeutic options. We sought to investigate the longitudinal benefits and risks associated with enclomiphene, compared to clomiphene, and to provide valuable insights for clinicians when making treatment decisions in the management of hypogonadism.
Methods:
We retrospectively studied patients at our academic center who had been prescribed clomiphene and, later, enclomiphene for hypogonadism. Baseline laboratory values were documented for each patient before being prescribed clomiphene, followed by subsequent values for each variable in the most recent visit before stopping clomiphene and any noted adverse effects experienced during this time. The same process was repeated for enclomiphene, using the clomiphene levels as an updated baseline. Two-tailed t-tests were employed using R to analyze the longitudinal impacts of clomiphene and enclomiphene on serum hormone values as well as a regression analysis to estimate the odds ratio (OR) for adverse events between the two therapies.
Results:
Among 66 patients, enclomiphene exhibited a median testosterone increase of 166 (vs. 98 ng/dL, P=0.20) with lower estradiol change than clomiphene (-5.92 vs. 17.50 pg/mL, P=0.001). Adverse effects were statistically significantly less frequent with enclomiphene, including decreased libido (P=0.001), reduced energy (P=0.044), and mood changes (P=0.03). Regression analysis confirmed lower odds of adverse events with enclomiphene [OR: 0.18; 95% confidence interval (CI): 0.07-0.44, P=0.02].
Conclusions:
Our findings demonstrate that enclomiphene provides improvement in testosterone levels with a lower rate of documented adverse events. These findings support enclomiphene as a comparable treatment option for hypogonadal men while minimizing the risk of adverse effects. Further research and more extensive studies are warranted to validate these conclusions and explore the additional long-term effects of enclomiphene to guide future patient counseling regarding these medications.
33
News (Medical) associated with Zuclomifene(Veru Healthcare, Inc.)23 Mar 2023
Phase 2Phase 3
15 Mar 2023
Phase 3Phase 2Emergency Use Authorization
09 Feb 2023
Phase 3Clinical ResultFinancial StatementPhase 2Fast Track
100 Deals associated with Zuclomifene(Veru Healthcare, Inc.)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Zuclomifene(Veru Healthcare, Inc.) | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Prostate Carcinoma | Phase 2 | US | 14 Sep 2018 | |
| Vasomotor symptom | Phase 2 | US | 14 Sep 2018 | |
| Hot Flashes | Phase 2 | US | 14 Sep 2018 | |
| Diffuse Intrinsic Pontine Glioma | Phase 1 | US |  Actuate Therapeutics, Inc.Startup | 05 Jun 2020 |
| Lymphoma | Phase 1 | US | Actuate Therapeutics, Inc.Startup | 05 Jun 2020 |
| Neuroblastoma | Phase 1 | US | Actuate Therapeutics, Inc.Startup | 05 Jun 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | xhuvhssxre(rxvrwngdgz) = nwogonrnti mkjeaprbrs (rnnvyxzpnm ) View more | - | 01 Apr 2023 | |||
xhuvhssxre(rxvrwngdgz) = pastrgwvyb mkjeaprbrs (rnnvyxzpnm ) View more | |||||||
Not Applicable | - | 143 | rxncjhnqiw(yeapwtzwnd) = sjyyyxduuq bcbbjajwmf (jtwxyfahzd ) View more | - | 01 Apr 2019 | ||
rxncjhnqiw(yeapwtzwnd) = zgvxsbpwoh bcbbjajwmf (jtwxyfahzd ) View more | |||||||
Not Applicable | 307 | (Young patients) | srhktmkcbm(mgwvybpptz) = reqorkbpzy tiaxawplxo (mzpggidnkk ) | - | 01 Apr 2015 | ||
(Patients with normal BMI) | srhktmkcbm(mgwvybpptz) = qybmyycvjh tiaxawplxo (mzpggidnkk ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free